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Preface —  About This Book
This book is intended for a law school survey course on food and drug regula-
tion. It covers the Food and Drug Administration’s (FDA’s) regulation of food, food 
additives, dietary supplements, drugs, animal drugs, medical devices, combination 
products, biologics, HCT/Ps ( human cells, tissues, and cellular and tissue- based 
products), cosmetics, color additives, and tobacco products. It also covers admin-
istrative procedure, regulation of research, FDA enforcement, federal preemption, 
and regulation of imports. It pre sents more  limited material on related areas regu-
lated primarily by other agencies.1 In addition to covering this substantive material, 
the book  will introduce you to the pro cess of understanding a complex statute, its 
implementing regulations, and related enforcement policies.
The book’s coverage is not intended to be comprehensive. Several existing books 
pre sent treatise- level coverage and even  those cannot cover FDA’s regulatory pro-
grams comprehensively. This book instead focuses on core aspects of selected FDA 
regulatory programs in the areas of food and medical products.2
Food and drug regulation is primarily a statutory and regulatory subject. Accord-
ingly, this book relies on a dif fer ent set of documents and a dif fer ent style of pre sen-
ta tion than a typical casebook. The book emphasizes guided reading of the Federal 
Food, Drug, and Cosmetic Act, related statutes, FDA regulations, and Federal Reg-
ister documents. Cases are presented primarily when they involve major issues of 
statutory interpretation, are historically significant, or are in one of the areas — 
such as federal preemption —  where case law plays a major role in the overall regula-
tory scheme. Cases are also included where they provide a concise discussion of a 
regulatory program or a useful illustration of a concept.
This book is designed to work as a set with the accompanying Statutory & Regu-
latory Supplement (Supplement). The Supplement is available  free, in PDF format, 
on this book’s page of the Carolina Academic Press website.3 The statutes and regu-
lations in the Supplement have been aggressively edited, like the cases in a typical 
1.  These include USDA- regulated foods (meat, eggs, poultry, and fish of the order siluriformes 
(catfish and related species)), agricultural biotechnology, alcohol, controlled substances, and vet-
erinary biologics.
2.  The main categories the book does not address are animal food and feed, radiation- emitting 
products, and medical gases.
3.  See https:// cap - press . com / books / isbn / 9781531004453 / Food - and - Drug - Regulation.
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law school casebook, to emphasize  those aspects that are most impor tant to a gen-
eral understanding of the subject.
Structure of the Book
The book is or ga nized around the structure of the Federal Food, Drug, and Cos-
metic Act of 1938 (FFDCA) and the relevant portion of the Public Health Ser vices 
Act (PHSA).4 This means that Chapter IV products (food, food additives, and dietary 
supplements), Chapter V products (drugs, animal drugs, medical devices, and com-
bination products), and PHSA products (biologics and HCT/Ps) are each grouped 
together. The single- product- category chapters —  Chapter VI (cosmetics), Chapter 
VII (color additives), and Chapter IX (tobacco products) —  are then included in a 
final, catch- all group. Parts I, II, and VII of the book address cross- cutting issues, 
while Parts III, IV, V, and VI address the four groups of individual product catego-
ries. Part VIII contains the appendices.
Part I of the book introduces the basic structure of FDA and the FFDCA. Within 
Part I, Chapter 1 addresses the structure of the agency and the product categories 
set out in the FFDCA. Chapter 2 addresses administrative procedure. It contains 
material on administrative procedure generally and on administrative procedure 
specific to FDA.
Part II of the book addresses regulation of research, marketing authorization, 
and background regulatory requirements associated with marketing authorization. 
This Part emphasizes  those aspects of research, marketing authorization, and 
background requirements that are similar across multiple product categories. 
Within Part II, Chapter 3 addresses regulation of research. It focuses on FDA 
regulation of human- subject research. Chapter 4 addresses marketing authorization. 
It contains material on pathways to market, designations, and access before 
market authorization. Chapter 5 addresses background requirements associated 
with marketing authorization. It contains information on production-process 
requirements, labeling requirements, establishment registration requirements, user 
fees, and postmarket requirements.
Part III of the book addresses  those products regulated primarily  under 
Chapter IV of the FFDCA. Chapter 6 addresses food, Chapter 7 addresses food 
additives, and Chapter 8 addresses dietary supplements. Chapter 9 does not address 
a single product category. Instead, it contains material on label claims for the two 
Chapter IV categories —  food and dietary supplements —  for which label- claim 
4.  Please note that this book uses: Roman numerals when referring to parts of this book (Part V); 
Arabic numerals when referring to parts of the CFR (21 C.F.R. Part 5); Arabic numerals when refer-
ring to chapters of this book (Chapter 5); and roman numerals when referring to chapters of the 
FFDCA (Chapter V).
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issues arise. Label claims receive a separate chapter to avoid presenting duplicative 
material in the  earlier chapters on food and dietary supplements.
Part IV of the book addresses  those products regulated primarily  under 
 Chapter V of the FFDCA. Chapter 10 addresses drugs, Chapter 11 addresses animal 
drugs, Chapter 12 addresses medical devices, and Chapter 13 addresses combina-
tion products.
Part V of the book addresses  those products regulated primarily  under the PHSA. 
Chapter 14 addresses  those aspects of biological products regulated primarily by the 
PHSA.5 Chapter 15 addresses HCT/Ps.
Part VI of the book addresses  those products regulated  under the FFDCA Chap-
ters VI, VII, and IX. Chapter 16 addresses cosmetics, Chapter 17 addresses color 
additives, and Chapter 18 addresses tobacco products.
Part VII returns to cross- cutting issues of the type addressed in Parts I and II. 
Chapter 19 addresses FDA enforcement, Chapter 20 addresses federal preemption, 
and Chapter 21 addresses regulation of imports.
Part VIII is an appendix recommending further reading. Its focus is on books 
rather than academic articles, with a par tic u lar emphasis on items available as 
audiobooks (a wonderful help to the busy  lawyer during commuting or exercise). 
It includes both law- specific reading and material on scientific, technological, and 
industrial developments relevant to food and drug regulation.
For a description of the structure of individual chapters, see “Introduction to this 
Book” in Chapter 1, Part A.
Citation Format and Editorial Approach
I have aggressively edited the documents that I have excerpted in this book. My 
goal in  doing this is to emphasize  those aspects of the excerpted documents that are 
most relevant to basic goal of this book: presenting an approachable overview of the 
basic structure of food and drug regulation.
Citations in this book conform generally to the 20th edition of The Bluebook: 
A Uniform System of Citation. Significant exceptions are the following:
I have cited Federal Register documents in a format that emphasizes the date of 
publication and type of document, rather than document title. I have done this for 
two reasons. First,  these documents frequently contain cumbersome multipart titles 
that —  despite their length —  are of only limited value in describing the document’s 
5.  As you  will see  later, all products meeting the statutory definition of biological product, 
PHSA § 351(i)(1), also meet the statutory definition of drug, FFDCA § 201(g)(1). Accordingly, 
much of this chapter of the book is focused on the relationship between FDA’s biologics division 
(transferred from the National Institute of Health to FDA in the 1970s) and FDA’s drugs division.
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content. Second, the administrative rulemaking pro cess typically results in multiple 
documents with very similar titles. This book uses the format below, which I believe 
 will help you distinguish more clearly between the dif fer ent documents cited:
[date of publication in YYYY- MM- DD format] [abbreviated agency name 
(FDA, USDA, EPA,  etc.)] [type of document (notice, proposed rule, final rule, 
 etc.)], [title or shortened title] [FR volume #] Fed. Reg. [FR page #]
Within quoted original sources, the original citation format is retained except 
where I have determined that a modification  will increase clarity or make the docu-
ment more readable.
Also within quoted original sources, I have made the following omissions with-
out any indication in the text:
• omitted most citations and footnotes, retaining only  those that I believe  will be 
of use to the reader (retained footnotes have their original numbering);
• omitted most quotation marks in situations where courts are simply quoting 
the language of prior judicial opinions as part of their own sentences (in the 
standard style of judicial opinion- writing);6
• modified the format of some retained citations to conform to the style of this 
book;
• replaced the use of a series of asterisks (common in older documents) with the 
modern use of three- dot or four- dot ellipses, as appropriate;
• omitted text from the part of an excerpted document that precedes the quoted 
language.
Where I have omitted text from a quoted source, I have used three- dot ellipses to 
indicate omissions of less than a sentence and four- dot ellipses to indicate omissions 
of a full sentence or more.
Within quotations and excerpts referencing the FFDCA or the PHSA, I have 
replaced references to U.S. Code section numbers with references to the correspond-
ing FFDCA section numbers, following the standard approach in this book. Where 
I have done this, I have used the notation “[FFDCA §]” to indicate the change.
One final editorial convention bears emphasis. Both the FFDCA and the PHSA 
are phrased in terms of authorities granted to, and obligations imposed upon, 
“the Secretary” — meaning the Secretary of Health and Human Services — rather 
than FDA. See FFDCA § 201(d). The Secretary of Health and Human Services, 
however, has delegated nearly all of the authority to administer these statutes to 
the Commissioner of Food and Drugs. See FDA Staff Manual Guides, Volume 
6.  This is necessary to facilitate omission of citations to the quoted documents, with the aim of 
making  those excerpts more readable. I have done this only in excerpts, not within the text of the 
book. Even within excerpts, I have never intentionally omitted quotation marks from sources other 
than judicial opinions.
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II — Delegations of Authority § 1410.10 (Effective Date: August 26, 2016). To 
make textual descriptions of statutory language more readable, I have generally 
substituted “FDA” for “the Secretary” in describing the language of the statute. This 
means that:
• In places where the FFDCA grants “the Secretary” authority to take a particu-
lar action, I typically describe it as granting “FDA” such authority. 
• In places where the FFDCA requires “the Secretary” to take some action, I typ-
ically describe it as requiring “FDA” to take such action.
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Chapter 1
Agency Structure and  
Product Categories
A. Introduction
1.  Introduction to This Casebook
As noted in the Preface, this book is designed to work as a set with the accompa-
nying Statutory & Regulatory Supplement (Supplement).1 The statutes and regula-
tions in the Supplement have been aggressively edited, like the cases in a typical law 
school casebook, to emphasize  those aspects that are most impor tant to a general 
understanding of the subject.
Primary Document Types
The primary document types included in this book and its Supplement are: 
codified statutory materials, calendar- based statutory materials, codified regu-
latory materials, calendar- based regulatory materials, judicial decisions, formal 
agency guidance, and agency website materials. Each of  these document types is 
explained below. Students new to regulatory work often won der about the relation-
ship between statutes and regulations, and between calendar- based and codified 
materials. That is addressed in more detail further below.
• Codified statutory materials.  These are the U.S. statutes as collected and or ga-
nized into the 54 Titles of the United States Code (USC). This book deals pri-
marily with material from Title 21 —  Food and Drugs. It also addresses some 
material from other titles, including Title 5 —  Government Organ ization and 
Employees, Title 7 —  Agriculture, Title 15 —  Commerce and Trade, Title 18 — 
Crimes and Criminal Procedure, Title 35 —  Patents, and Title 42 —  The Public 
Health and Welfare.
The Federal Food, Drug, and Cosmetics Act of 1938 (FFDCA), as amended, is 
codified in Chapter 9 of Title 21. The Public Health Ser vices Act (PHSA), as 
amended, is codified in Chapter 6A of Title 42. When referencing  these two 
statutes, this book follows the standard practice among food- and- drug  lawyers 
of referring to the section numbers of the amended statutes, rather than the 
numbers for the corresponding section of the U.S. Code. The FFDCA section 
1.  The Supplement is available  free, in PDF format, on the Carolina Academic Press website.
Copyright © 2021 Carolina Academic Press, LLC. All rights reserved. 
4 1 · AGENCY STRUCTURE AND PRODUCT CATEGORIES
numbers correspond to the relevant chapters of the statute and are much easier 
to remember than the section numbers in the U.S. Code.2
• Calendar- based statutory materials.  These are the  actual statutes as enacted 
through the pro cess specified in Article I, Section 7 of the U.S. Constitution. 
 These are published as Public Laws, with a number corresponding to the rel-
evant session of Congress,3 a hyphen, and a number assigned in ascending order 
from the beginning of that congressional session. They are also published in 
the U.S. Statutes at Large.
• Codified regulatory materials.  These are the regulations (laws promulgated by 
executive branch agencies  under delegated statutory authority) of the United 
States as collected and or ga nized into the 50 titles of the U.S. Code of Federal 
Regulations (CFR). This book deals primarily with material from Title 21 — 
Food and Drugs. It also references some materials from other titles, including 
Title 7 —  Agriculture, Title 9 —  Animals and Animal Products, and Title 16 — 
Commercial Practices.4
• Calendar- based regulatory materials.  These are the vari ous documents pub-
lished in the Federal Register (FR), the official, chronological rec ord of the 
executive branch.  These include, most importantly, proposed rules for com-
ment and final rules that  will be codified as part of the CFR. They also include 
notices of vari ous  matters, including the availability of guidance documents 
(which are not themselves published in the FR). Many proposed and final rules 
from recent de cades include a preamble stating publicly the reasons for the 
relevant agency action. But older proposed and final rules rarely contain an 
explanatory preamble. Where an explanatory preamble is available, it can be 
helpful to read it much as you would read the reasoning of a court decision 
(and, at times, with the same healthy dose of skepticism).
• Judicial decisions.  These are, of course, the core content of a traditional law 
school casebook in a common- law field.  Because food and drug regulation is 
a statutory field, they play less of a role  here. In most chapters of this book, 
judicial decisions are included when they resolve major issues of statutory 
2.  For example, when referring to the “Definitions; generally” provision of the statute, the 
book  will refer to FFDCA § 201, rather than 21 U.S.C. § 321. To avoid overwhelming you with 
section numbers, parallel citations to the U.S. Code are included in the statutory supplement but 
not in the book itself.
3.  The 1st Congress sat from March 1789 to March 1791; the 116th Congress sits from 
January 2019 to January 2021.
4.  Note that title numbers in the CFR sometimes match title numbers in the USC, but sometimes 
do not. Title 21 carries the title “Food and Drugs” in both the USC and the CFR. However, CFR 
Title 21 includes some regulations based on statutes outside of USC Title 21 (such as the Public 
Health Ser vices Act, codified in USC Title 42). In many other regulatory areas, the numbers do 
not match at all. For example, the primary statutes administered by the Securities and Exchange 
Commission are codified in Title 15 of the USC. However, the regulations of the Securities and 
Exchange Commission are codified in Title 17 of the CFR.
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or constitutional interpretation. They are also occasionally included when 
they provide a concise summary of a par tic u lar aspect of food and drug 
regulation. They play a larger role in Chapter 20 on federal preemption.
• Formal agency guidance.  These are the documents published by FDA  under 
procedures set out in FFDCA § 701(h) and 21 C.F.R. § 10.115 —  Good Guidance 
Practices. They do not bind FDA or regulated parties, but nonetheless play a 
large role in communicating FDA’s expectations to regulated parties.
• Agency website materials.  These are simply materials from FDA’s website that do 
not qualify as formal agency guidance. In general, this book prefers excerpts 
from the other above document types to agency website materials. However, 
 there are some situations where website materials are available in an area where 
other document types are not. At other times, an agency website provides a 
more concise and approachable explanation than other document types. In 
 those situations, website materials are included.
The Relationship between Codified and Calendar- Based Materials
Statutory materials Regulatory materials
Calendar- based
(or ga nized by date)
Statutes promulgated (through 
Congress/president interaction) 
on a par tic u lar date; legislative 
history materials
Every thing published in federal 
register; items that have their 
availability announced in federal 
register (but themselves made available 
online —  guidance documents are the 
most prominent example)
Codified
(or ga nized by 
subject  matter)
The 54 titles of the USC
Statutes, but not legislative 
history materials, are codified
The 50 titles of the CFR
The regulations promulgated by a final 
rule (but not its preamble, and not other 
federal register documents) are codified
Where to Find the Dif fer ent Document Types
With rare exceptions, the text of codified statutory and regulatory materials is 
included only in the Supplement, and not in this casebook. This is done for two 
reasons. First, this  will help you learn the structure of the statute and regulations, 
as you  will always see them set out in the order in which they are codified. Sec-
ond, you  will find yourself referring repeatedly to the same statutory sections (but 
often dif fer ent subsections) in dif fer ent parts of the course. You  will understand 
the interactions between  these sections and subsections much better when you 
return to a page in the Supplement you have read —  and ideally begun to mark 
up —  previously.
In the book itself, you  will find the remaining document types: excerpts of judi-
cial decisions, calendar- based regulatory materials, formal agency guidance, and 
agency website materials.
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Structure of Individual Chapters
Most chapters begin by requesting that you read (or review, as appropriate) spe-
cific statutory and regulatory sections in the Supplement. The idea  behind this is to 
allow you to become familiar with the language and structure of the statute itself, 
rather than simply reading out- of- context quotations.
Each chapter then contains,  under the heading Outline of Regulatory Regime, sev-
eral charts.5 None of  these is intended to be comprehensive, as comprehensive charts 
would provide too much detail to be useful. Instead, they are intended to give you a 
general sense of the statutory history, statutory structure, and regulatory structure 
relevant to the topics addressed in that chapter.
First, a “Timeline of Key Statutes” chart sets out, in chronological order, the 
key calendar- based statutory material. The idea is to give you a historical sense of 
the times that statutory change has occurred. How much you should focus on this 
depends on the style of your professor. If you have a historically minded professor, 
this chart  will serve as a reference point for you as your professor discusses statu-
tory changes over time. If your professor is focused more on current law, you should 
spend less time with this chart and more with  those that follow.
Second, a “Key Statutory Provisions” chart sets out, in numerical order, the key 
sections and subsections of codified statutory material. This  will usually be a longer 
(and at times, much longer) list of sections than  those you are asked to read.6 This 
is likely the most impor tant of the charts included in each chapter. The idea is to 
give you an overview of the statutory structure in the relevant area. As your profes-
sor discusses current law, this chart should serve as a reference point for you on 
the major statutory provisions relevant to the regulatory area you are discussing. 
It should also serve as a starting point if you would like to learn more about some 
aspect of the area not covered in this book.
Third, a “Key Regulatory Provisions” chart sets out, in numerical order, the key 
parts and subparts (and occasionally sections and subsections) of codified regula-
tory material (in other words, CFR provisions).7 The idea is to give you an overview 
of the regulatory structure in the relevant area. The Supplement includes excerpts 
from only a small number of  these key regulatory provisions. Most are too long, and 
too technically detailed, to ask you to read their text in a one- semester course. What 
you should understand is that a large portion of the  actual law relevant to food and 
drug regulation is contained in this codified regulatory material. Few practicing 
 lawyers  will have read large numbers of  these provisions in their entirety. However, 
it is critical to know, for any par tic u lar regulatory area: (1) what codified provisions 
exist; (2) where to find them; and (3) what role they play (in relation to statutes and 
guidance) in the regulatory scheme.8
5.  In addition to, or instead of, the outline at the beginning of the chapter, a few chapters con-
tain a separate Outline of Regulatory Regime section for one or more subtopics.
6.  Portions of many, but not all, key statutory provisions are excerpted in the Supplement.
7.  This is sometimes a single chart and sometimes two or more charts grouped by subtopic.
8. The legal status of agency guidance is discussed in more detail in Chapter 2.
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As you read each chapter for the first time, you should do no more than skim 
 these charts to get a general sense of the structure of the laws and regulations rel-
evant to the topic of the chapter. As you begin to review the material at the end of 
the semester (or perhaps work on a seminar paper), you may find it helpful to look 
back at  these charts in more detail.
Following  these charts, most chapters contain vari ous additional parts, many of 
which contain excerpts from relevant documents. All chapters conclude with a “Key 
Points” section. This Key Points section is placed at the end of the chapter, as that is 
the point where it is likely to be most useful to you. However, you may also find it use-
ful to skip to the relevant Key Points section, and review it briefly, before you begin 
reading each chapter —  and then to review it again when you reach the chapter’s end.
The Relationship Between Codified and Uncodified Material  
(and Why It Is Necessary to Study Both)
Students often won der why, when codified statutory and regulatory materials are 
available, it is nonetheless impor tant to study non- codified materials as well. The 
answer is that non- codified materials provide information that is not available in 
the codified materials.
For statutory provisions, the U.S. Code is your best source of current law. But if 
you want to know when a par tic u lar provision was added to —  or removed from — 
the codified law, the individual statutes passed by Congress are your best source of 
information. Additionally, individual statutes  will be impor tant to you as a prac-
ticing  lawyer for a reason few students contemplate in law school. Once you begin 
practice, you  will find that the codified law —  as it existed at the time you began 
working in the field —  is the baseline structure for your understanding of the way 
that field works. Changes made by Congress  after you begin practicing in a field 
 will, at least initially, seem like awkward additions to that initial baseline. And you 
are likely to refer to them not as part of the FFDCA, but by the name of the indi-
vidual statute that made the relevant statutory changes. (“This is mandated by the 
21st  Century Cures Act,” rather than “This is mandated by the FFDCA.”)
The same applies, of course, to the se nior  lawyers for whom you are likely to 
work.  Unless you are conversant with the names and general content of the indi-
vidual statutes that have modified the FFDCA over time, you will not be able to 
communicate effectively with your colleagues.
For regulatory provisions, the CFR is your best source of current law.9 Like with 
statutes, it is necessary to turn to calendar- based materials —  in this case, the 
9.  For most purposes, the best way to access the CFR is the eCFR (“Electronic Code of Federal 
Regulations”) website maintained by the U.S. Government Publishing Office. It is  free, usually 
updated within a few days of any regulatory change, and —  most importantly —  formatted in a 
manner that allows you to view an entire regulatory “Part” rather than just an individual “Section.” 
In other words, it permits you to view all of 21 C.F.R. Part 101 —  Food Labeling on a single page, 
rather than requiring you to click individually on each subsection (21 C.F.R. §§ 101.1, 101.2, 101.15, 
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Federal Register —  to learn when a par tic u lar provision was added to, or removed 
from, the CFR. But, for regulations, calendar- based materials play an additional 
role. It is in  these calendar- based materials —  especially “Proposed Rules” and 
“Final Rules” —  that agencies  today set out the reasoning  behind their rulemaking 
decisions.
The Relationship Between Food & Drug Regulation  
and Administrative Law
Food & Drug Regulation is a course in a substantive regulatory field. In this 
manner, it is similar to law school courses in Securities Regulation or Environmen-
tal Law. The general course in Administrative Law is not a course in a substantive 
regulatory field. Instead, Administrative Law is a broad survey of the interactions 
among executive branch agencies, Congress, and the courts.
This book is designed to pre sent Food & Drug Regulation in a manner that is 
accessible to students who have not yet taken Administrative Law. It is also designed 
to avoid duplicating the coverage of an Administrative Law course.10 Past experience 
suggests two  things. First, students find that an  earlier course in Food & Drug Reg-
ulation makes the abstract concepts of Administrative Law easier to understand. 
Second, students find that an  earlier course in Administrative Law gives them some 
additional perspective on a  later course in a Food & Drug Regulation. In other 
words, whichever course you take first is likely to help you understand the course 
you take  later (or concurrently). And you  will learn more by taking both courses 
than by taking  either course alone.
2.  Introduction to This Chapter
This chapter introduces you to the history and structure of the U.S. Food and 
Drug Administration (FDA). The first part of the chapter focuses on the agency’s 
current structure and the historical context for the agency as it exists  today. The 
second part introduces a number of the product categories provided for in the Fed-
eral Food, Drug, and Cosmetic Act (FFDCA). It also introduces some of the dif-
ficulties involved in determining the category into which a par tic u lar product fits.
101.18,  etc.). Unfortunately,  there does not seem to be a single web link that has remained stable 
over time for the main eCFR landing page. Your best bet is to Google “eCFR gpo . gov” (including 
“gpo . gov” is impor tant, as “ecfr” alone sometimes turns up strange results).
10.  The necessary exception is the Chevron case and the provisions of the Administrative Proce-
dure Act discussed in the first part of Chapter 2 of this casebook. Chevron and the APA provisions 
 will have been covered in almost any Administrative Law course. But the remainder of Chapter 2, 
on FDA’s administrative procedures,  will be new material even to most alumni of a good Admin-
istrative Law course.
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Food and drug regulation is based around a  limited set of product categories. All 
of  these are set out in just a few statutory and regulatory provisions: FFDCA § 201, 
FFDCA § 503(g)(1), PHSA § 351, 21 C.F.R. §§ 3.2 and 1271.3(d).
FFDCA § 201  will provide you with the statutory definitions for most —  but not 
all —  FDA-regulated product categories. You  will want to bookmark that section, as 
you  will refer to it repeatedly throughout this course. PHSA § 351(i)  will provide you 
with the statutory definition of biological product (or biologic), which is not defined 
in FFDCA § 201. FFDCA § 503(g)(1)(A), together with 21 C.F.R. § 3.2,  will pro-
vide you with the definition of combination product. Fi nally, 21 C.F.R. § 1271.3(d) 
 will provide you with the regulatory definition of one product category that is not 
defined explic itly by statute —  human cells, tissues, and cellular and tissue- based 
products (HCT/Ps).
At this point, please read (or review) the following excerpts in the statutory 
supplement:
• FFDCA § 201. Definitions; generally.
• FFDCA § 503. Exemptions and considerations for certain drugs, devices, and 
biological products. Subsection (g)(1) only. [statutory reference to combination 
products]
• PHSA § 351. Regulations of biological products. Subsection (i) only.
• 21 C.F.R. § 3.2. [regulatory definition of “combination product”]
• 21 C.F.R. § 1271.3(d). [definition of “ Human cells, tissues, and cellular or 
tissue- based products” (HCT/Ps)]
Moving on from product categories, we turn to the core operational provision of 
the statute: FFDCA § 301. The first three subsections, FFDCA § 301(a)–(c), set out 
a general prohibition on adulteration and misbranding of FDA- regulated products. 
Much of the remainder of the FFDCA simply describes actions that  will make one 
of  these products adulterated or misbranded in violation of § 301. Other portions of 
FFDCA § 301 prohibit other, more specific actions.
At this point, please read (or review) the following excerpts in the statutory 
supplement:
• FFDCA § 301. Prohibited acts. Subsections (a), (b), and (c).
Fi nally, FFDCA § 1003(b) sets out FDA’s statutory mission statement. As you read 
this, note that it has more significance than the mission statement developed inter-
nally by a private sector or public sector organ ization. Instead, this mission state-
ment was prescribed in a major congressional effort to reform the agency, the FDA 
Modernization Act of 1997. Subsection (f) —  also part of that same 1997 statute — 
explic itly sets out Congress’s view that FDA was not then in compliance with its 
statutory obligations. It directed the agency to develop a plan to bring itself into stat-
utory compliance, and to report annually on its pro gress  toward such compliance.
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At this point, please read (or review) the following excerpts in the statutory 
supplement:
• FFDCA § 1003. Food & Drug Administration. Subsections (b) and (f) only.
B. Outline of Regulatory Regime
This is your first example of the “Outline of Regulatory Regime” described in 
the “Introduction to this Casebook” section, above. The first chart is a timeline of 
key statutes, listed in chronological order. The second chart is a list of key statutory 
provisions, listed in the order  those provisions appear in the FFDCA and PHSA. 
The third chart is a list of key regulatory provisions, listed in the order  those appear 
in the CFR. None of  these charts is intended to be comprehensive, as comprehensive 
charts would provide too much detail to be useful. Instead, they are intended to 
give you a general sense of the statutory history, statutory structure, and regulatory 
structure relevant to this casebook chapter.
As you read this chapter for the first time, you should do no more than skim  these 
charts to get a general sense of the structure of the applicable statutes and regulations. 
As you begin to review the material at the end of the semester (or perhaps work on 
a seminar paper), you may find it helpful to look back at  these charts in more detail. 
You should follow this same approach (skimming first, returning to read in more 
detail  later if necessary) in each “Outline of Regulatory Regimes” section of this book.
Timeline of Key Statutes: FDA Structure
Year PL Stat Name of Statute
1906 59-384 34 Stat. 768 Pure Food and Drug Act
1938 75-717 52 Stat. 1040 FFDCA of 1938
1988 100-607 102 Stat. 3048, 3120 Food and Drug Administration Act of 1988
1997 105-115 111 Stat. 2296 FDA Modernization Act of 1997
Timeline of Key Statutes: Product Categories
Year PL Stat Name of Statute
1906 59-384 34 Stat. 768 Pure Food and Drug Act
1938 75-717 52 Stat. 1040 FFDCA of 1938
1944 78-410 58 Stat. 682 Public Health Ser vices Act
1968 90-399 82 Stat. 342 Animal Drug Amendments of 1968
1976 94-295 90 Stat. 539 Medical Devices Amendments of 1976
1994 103-417 108 Stat. 4325 Dietary Supplement Health and Education Act of 1997
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Key Statutory Provisions: FDA Structure
Statute Name or U.S.C. Title § Title of Section or Subsection
FFDCA 1001 Separability clause
FFDCA 1003 Food and Drug Administration
FFDCA 1003a Office of Pediatric Therapeutics
FFDCA 1004 Scientific review groups
FFDCA 1007 Contracts for expert review
FFDCA 1010 Office of the Chief Scientist
FFDCA 1011 Office of  Women’s Health
21 U.S.C. 399g Food and Drug Administration Intercenter 
Institutes
Key Statutory Provisions: Product Categories
Statute Name or U.S.C. Title § Title of Section or Subsection
FFDCA 201 Definitions
FFDCA 503(g) Regulation of combination products
FFDCA 563 Classification of products
Key Statutory Provisions: Adulteration and Misbranding
Statute Name or U.S.C. Title § Title of Section or Subsection
FFDCA 201 Definitions
FFDCA 301 Prohibited acts
FFDCA 402, 501, 
601, 902
Chapter- specific adulteration provisions
  402: food
  501: drugs, devices, biologics, combination 
products
  601: cosmetics
  902: tobacco products
FFDCA 403, 502, 
602, 903
Chapter- specific misbranding provisions
  403: food
  502: drugs, devices, biologics, combination 
products
  602: cosmetics
  903: tobacco products
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Key Regulatory Provisions: FDA Structure
21 C.F.R.  
Part
Subpart Title of Part or Subpart
5  —  Organ ization
Key Regulatory Provisions: Product Categories
21 C.F.R.  
Part
Subpart Title of Part or Subpart
3  —  Product jurisdiction
1270  —   Human tissue intended for transplantation
1271  —   Human cells, tissues, and cellular and tissue- based products
C. Historical Context
1.  Orga nizational History
The excerpt immediately below, from FDA’s website, summarizes the orga-
nizational history of FDA and its pre de ces sor entities.
FDA Website, History of FDA’s Internal Organ ization:  
Brief Orga nizational History*
In his 1837 annual report, Patent Commissioner Henry L. Ellsworth rec-
ommended a national agency for the encouragement of agriculture. Congress 
responded in 1839 by an appropriation of $1000 to the Commissioner of Patents for 
“the collection of agricultural statistics, and for other agricultural purposes.” From 
then on, the Patent Office collected and reported agricultural statistics, sponsored 
or conducted chemical investigations on agricultural  matters, monitored agricul-
tural developments, and reported on all of  these in its annual reports. Beginning 
in 1849, a separate report was made by the Patent Commissioner to Congress on 
agricultural  matters. An Agricultural Division was established in the Patent Office 
and a chemical laboratory was created in that Division.
When the U.S. Department of Agriculture was created in 1862, the Patent Office’s 
Agricultural Division was transferred to the new Department, becoming the Divi-
sion of Chemistry in 1890 and the Bureau of Chemistry in 1901. In 1927, the Bureau 
of Chemistry became the United States Food, Drug and Insecticide Administra-
tion, and in 1930 the name was shortened to the U.S. Food and Drug Administra-
tion. Ten years  later, in 1940, the FDA was transferred from the U.S. Department 
of Agriculture to the newly created Federal Security Agency, which was renamed 
* From https:// www . fda . gov / about - fda / history - fdas - fight - consumer - protection - and - public 
- health / history - fdas - internal - organization (last updated January 31, 2018).
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the Department of Health Education and Welfare in 1953, and again renamed the 
Department of Health and  Human Ser vices in 1979.
2.  FDA’s “Milestones” List
For some time now, FDA’s History Office has maintained a list of “Milestones in 
U.S. Food and Drug Law History.” The most recent version at the time of this writ-
ing is excerpted below. Experience suggests that this is a useful document for  those 
seeking to learn food and drug regulation. You may find it helpful to bookmark this 
list and refer to it  later in the semester when you are trying to consolidate what you 
have learned. Many of the milestones on this list  will be more meaningful to you 
 after you have covered the relevant topics in more detail.
FDA Website, Milestones in U.S. Food and Drug Law History*
From the beginnings of civilization  people have been concerned about the qual-
ity and safety of foods and medicines. In 1202, King John of  England proclaimed the 
first En glish food law, the Assize of Bread, which prohibited adulteration of bread 
with such ingredients as ground peas or beans. Regulation of food in the United 
States dates from early colonial times. Federal controls over the drug supply began 
with inspection of imported drugs in 1848, although the first federal biologics law, 
which addressed the provision of reliable smallpox vaccine to citizens, was passed 
in 1813. The following chronology describes some of the milestones in the history of 
food and drug regulation in the United States.
1820
 Eleven physicians meet in Washington, D.C., to establish the U.S. Pharmaco-
peia, the first compendium of standard drugs for the United States.
1848
 Drug Importation Act passed by Congress requires U.S. Customs Ser vice 
inspection to stop entry of adulterated drugs from overseas.
1862
 President Lincoln appoints a chemist, Charles M. Wetherill, to serve in the 
new Department of Agriculture. This was the beginning of the Bureau of 
Chemistry, the pre de ces sor of the Food and Drug Administration.
1880
 Peter Collier, chief chemist, U.S. Department of Agriculture, recommends 
passage of a national food and drug law, following his own food adulteration 
investigations. The bill was defeated, but during the next 25 years more than 
100 food and drug bills  were introduced in Congress.
* From: https:// www . fda . gov / about - fda / fdas - evolving - regulatory - powers / milestones - us - food 
- and - drug - law - history (last updated January 31, 2018).
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1883
 Dr. Harvey W. Wiley becomes chief chemist, expanding the Bureau of Chem-
istry’s food adulteration studies. Campaigning for a federal law, Dr. Wiley is 
called the “Crusading Chemist” and “ Father of the Pure Food and Drugs Act.” 
He retired from government ser vice in 1912 and died in 1930.
1897
 Tea Importation Act passed, providing for Customs inspection of all tea 
entering U.S. ports, at the expense of the importers.
1898
 Association of Official Agricultural Chemists (now AOAC International) 
establishes a Committee on Food Standards headed by Dr. Wiley. States begin 
incorporating  these standards into their food statutes.
1902
 The Biologics Control Act is passed to ensure purity and safety of serums, 
vaccines, and similar products used to prevent or treat diseases in  humans.
 Congress appropriates $5,000 to the Bureau of Chemistry to study chemical 
preservatives and colors and their effects on digestion and health. Dr. Wiley’s 
studies draw widespread attention to the prob lem of food adulteration. Public 
support for passage of a federal food and drug law grows.
1906
 The original Food and Drugs Act is passed by Congress on June 30 and signed 
by President Theodore Roo se velt. It prohibits interstate commerce in mis-
branded and adulterated foods, drinks and drugs.
 The Meat Inspection Act is passed the same day.
 Shocking disclosures of insanitary conditions in meat- packing plants, the use 
of poisonous preservatives and dyes in foods, and cure- all claims for worth-
less and dangerous patent medicines  were the major prob lems leading to the 
enactment of  these laws.
1907
 First Certified Color Regulations, requested by manufacturers and users, list 
seven colors found suitable for use in foods.
1911
 In U.S. v. Johnson, the Supreme Court rules that the 1906 Food and Drugs 
Act does not prohibit false therapeutic claims but only false and misleading 
statements about the ingredients or identity of a drug.
1912
 Congress enacts the Sherley Amendment to over come the ruling in U.S. v. 
Johnson. It prohibits labeling medicines with false therapeutic claims intended 
to defraud the purchaser, a standard difficult to prove.
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 Mrs. Winslow’s Soothing Syrup for teething and colicky babies, unlabeled yet 
laced with morphine, killed many infants.
1913
 Gould Amendment requires that food package contents be “plainly and con-
spicuously marked on the outside of the package in terms of weight, mea sure, 
or numerical count.”
1914
 In U.S. v. Lexington Mill and Elevator Com pany, the Supreme Court issues 
its first ruling on food additives. It ruled that in order for bleached flour with 
nitrite residues to be banned from foods, the government must show a rela-
tionship between the chemical additive and the harm it allegedly caused in 
 humans. The court also noted that the mere presence of such an ingredient 
was not sufficient to render the food illegal.
 The Harrison Narcotic Act requires prescriptions for products exceeding the 
allowable limit of narcotics and mandates increased record- keeping for physi-
cians and pharmacists who dispense narcotics.
1924
 In U.S. v. 95 Barrels Alleged Apple Cider Vinegar, the Supreme Court rules 
that the Food and Drugs Act condemns  every statement, design, or device on 
a product’s label that may mislead or deceive, even if technically true.
1927
 The Bureau of Chemistry is reor ga nized into two separate entities. Regulatory 
functions are located in the Food, Drug, and Insecticide Administration, and 
nonregulatory research is located in the Bureau of Chemistry and Soils.
1930
 McNary- Mapes Amendment authorizes FDA standards of quality and fill- of- 
container for canned food, excluding meat and milk products.
 The name of the Food, Drug, and Insecticide Administration is shortened to 
Food and Drug Administration (FDA)  under an agricultural appropriations 
act.
1933
 FDA recommends a complete revision of the obsolete 1906 Food and Drugs 
Act. The first bill is introduced into the Senate, launching a five- year legisla-
tive  battle.
1935
 U.S. Government begins publication of the Federal Register.
1937
 Elixir of Sulfanilamide, containing the poisonous solvent diethylene gly-
col, kills 107 persons, many of whom are  children, dramatizing the need to 
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establish drug safety before marketing and to enact the pending food and 
drug law.
1938
 The Federal Food, Drug, and Cosmetic (FDC) Act of 1938 is passed by Con-
gress, containing new provisions:
 Extending control to cosmetics and therapeutic devices.
 Requiring new drugs to be shown safe before marketing- starting a new system 
of drug regulation.
 Eliminating the Sherley Amendment requirement to prove intent to defraud 
in drug misbranding cases.
 Providing that safe tolerances be set for unavoidable poisonous substances.
 Authorizing standards of identity, quality, and fill- of- container for foods.
 Authorizing factory inspections.
 Adding the remedy of court injunctions to the previous penalties of seizures 
and prosecutions.
  Under the Wheeler- Lea Act, the Federal Trade Commission is charged with 
overseeing advertising associated with products other wise regulated by FDA.
1939
 First Food Standards issued (canned tomatoes, tomato purée, and tomato 
paste).
1940
 FDA transferred from the Department of Agriculture to the Federal Secu-
rity Agency, with Walter G. Campbell appointed as the first Commissioner of 
Food and Drugs.
1941
 Insulin Amendment requires FDA to test and certify purity and potency of 
this lifesaving drug for diabetes
1943
 In U.S. v. Dotterweich, the Supreme Court rules that the responsible officials 
of a corporation, as well as the corporation itself, may be prosecuted for viola-
tions. It need not be proven that the officials intended, or even knew of, the 
violations.
1944
 Public Health Ser vice Act is passed, covering a broad spectrum of health con-
cerns, including regulation of biological products and control of communi-
cable diseases.
1945
 Penicillin Amendment requires FDA testing and certification of safety and 
effectiveness of all penicillin products.  Later amendments extended this 
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requirement to all antibiotics. In 1983 such control was found no longer 
needed and was abolished.
1948
 Miller Amendment affirms that the [FFDCA] applies to goods regulated by 
the Agency that have been transported from one state to another and have 
reached the consumer.
1949
 FDA publishes guidance to industry for the first time. This guidance, “Pro-
cedures for the Appraisal of the Toxicity of Chemicals in Food,” came to be 
known as the “black book.”
1950
 In Alberty Food Products Co. v. U.S., a court of appeals rules that the direc-
tions for use on a drug label must include the purpose for which the drug is 
offered. Therefore, a worthless remedy cannot escape the law by not stating 
the condition it is supposed to treat.
 Oleomargarine Act requires prominent labeling of colored oleomargarine, to 
distinguish it from butter.
 Delaney Committee starts congressional investigation of the safety of chemi-
cals in foods and cosmetics, laying the foundation for the 1954 Miller Pesti-
cide Amendment, the 1958 Food Additives Amendment, and the 1960 Color 
Additive Amendment.
1951
 Durham- Humphrey Amendment defines the kinds of drugs that cannot be 
safely used without medical supervision and restricts their sale to prescription 
by a licensed practitioner.
1952
 In U.S. v. Cardiff, the Supreme Court rules that the factory inspection provi-
sion of the 1938 FDC Act is too vague to be enforced as criminal law.
 FDA consumer con sul tants are appointed in each field district to maintain 
communications with consumers and ensure that FDA considers their needs 
and prob lems.
1953
 Federal Security Agency becomes the Department of Health, Education, and 
Welfare (HEW).
 Factory Inspection Amendment clarifies previous law and requires FDA to 
give manufacturers written reports of conditions observed during inspections 
and analyses of factory samples.
1954
 Miller Pesticide Amendment spells out procedures for setting safety limits for 
pesticide residues on raw agricultural commodities.
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 First large- scale radiological examination of food carried out by FDA when it 
received reports that tuna suspected of being radioactive was being imported 
from Japan following atomic blasts in the Pacific. FDA begins monitoring 
around the clock to meet the emergency.
1955
 HEW Secretary Oveta Culp Hobby appoints a committee of 14 citizens to 
study the adequacy of FDA’s facilities and programs. The committee recom-
mends a substantial expansion of FDA staff and facilities, a new headquarters 
building, and more use of educational and informational programs.
 The Division of Biologics Control became an in de pen dent entity within the 
National Institutes of Health,  after polio vaccine thought to have been inacti-
vated is associated with about 260 cases of polio.
1958
 Food Additives Amendment enacted, requiring manufacturers of new food 
additives to establish safety. The Delaney proviso prohibits the approval of 
any food additive shown to induce cancer in  humans or animals.
 FDA publishes in the Federal Register the first list of substances generally rec-
ognized as safe (GRAS). The list contains nearly 200 substances.
1959
 U.S. cranberry crop recalled three weeks before Thanksgiving for FDA tests 
to check for aminotriazole, a weedkiller found to cause cancer in laboratory 
animals. Cleared berries  were allowed a label stating that they had been tested 
and had passed FDA inspection, the only such endorsement ever allowed by 
FDA on a food product.
1960
 Color Additive Amendment enacted, requiring manufacturers to establish 
the safety of color additives in foods, drugs and cosmetics. The Delaney pro-
viso prohibits the approval of any color additive shown to induce cancer in 
 humans or animals.
 Federal Hazardous Substances Labeling Act, enforced by FDA, requires 
prominent label warnings on hazardous  house hold chemical products.
1962
 Thalidomide, a new sleeping pill, is found to have caused birth defects in 
thousands of babies born in western Eu rope. News reports on the role of 
Dr. Frances Kelsey, FDA medical officer, in keeping the drug off the U.S. mar-
ket, arouse public support for stronger drug regulation.
 Kefauver- Harris Drug Amendments passed to ensure drug efficacy and 
greater drug safety. For the first time, drug manufacturers are required to 
prove to FDA the effectiveness of their products before marketing them. The 
new law also exempts from the Delaney proviso animal drugs and animal 
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feed additives shown to induce cancer but which leave no detectable levels of 
residue in the  human food supply.
 Consumer Bill of Rights is proclaimed by President John F. Kennedy in a 
message to Congress. Included are the right to safety, the right to be informed, 
the right to choose, and the right to be heard.
1965
 Drug Abuse Control Amendments are enacted to deal with prob lems caused 
by abuse of depressants, stimulants and hallucinogens.
1966
 FDA contracts with the National Acad emy of Sciences/National Research 
Council to evaluate the effectiveness of 4,000 drugs approved on the basis of 
safety alone between 1938 and 1962.
 Child Protection Act enlarges the scope of the Federal Hazardous Substances 
Labeling Act to ban hazardous toys and other articles so hazardous that ade-
quate label warnings could not be written.
 Fair Packaging and Labeling Act requires all consumer products in interstate 
commerce to be honestly and informatively labeled, with FDA enforcing pro-
visions on foods, drugs, cosmetics, and medical devices.
1968
 FDA Bureau of Drug Abuse Control and Trea sury Department Bureau of 
Narcotics are transferred to the Department of Justice to form the Bureau of 
Narcotics and Dangerous Drugs (BNDD), consolidating efforts to police traf-
fic in abused drugs.
 Reor ga ni za tion of federal health programs places FDA in the Public Health 
Ser vice.
 FDA forms the Drug Efficacy Study Implementation (DESI) to implement 
recommendations of the National Acad emy of Sciences investigation of effec-
tiveness of drugs first marketed between 1938 and 1962.
 Animal Drug Amendments place all regulation of new animal drugs  under 
one section of the Food, Drug, and Cosmetic Act — Section 512 —  making 
approval of animal drugs and medicated feeds more efficient.
1969
 FDA begins administering Sanitation Programs for milk, shellfish, food ser-
vice, and interstate travel facilities, and for preventing poisoning and acci-
dents.  These responsibilities  were transferred from other units of the Public 
Health Ser vice.
 The White House Conference on Food, Nutrition, and Health recommends 
systematic review of GRAS substances in light of FDA’s ban of the artificial 
sweetener cyclamate. President Nixon  orders FDA to review its GRAS list.
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1970
 In Upjohn v. Finch the Court of Appeals upholds enforcement of the 1962 
drug effectiveness amendments by ruling that commercial success alone does 
not constitute substantial evidence of drug safety and efficacy.
 FDA requires the first patient package insert: oral contraceptives must con-
tain information for the patient about specific risks and benefits.
 Drug Abuse Prevention and Control Act replaces previous laws and catego-
rizes drugs based on abuse and addiction potential compared to their thera-
peutic value.
 Environmental Protection Agency established; takes over FDA program for 
setting pesticide tolerances.
1971
 PHS Bureau of Radiological Health transferred to FDA. Its mission: protec-
tion against unnecessary  human exposure to radiation from electronic prod-
ucts in the home, industry, and the healing arts.
 National Center for Toxicological Research is established in the biologi-
cal facilities of the Pine Bluff Arsenal in Arkansas. Its mission is to examine 
biological effects of chemicals in the environment, extrapolating data from 
experimental animals to  human health.
 Artificial sweetener saccharin, included in FDA’s original GRAS list, is 
removed from the list pending new scientific study.
1972
 Over- the- Counter Drug Review begun to enhance the safety, effectiveness 
and appropriate labeling of drugs sold without prescription.
 Regulation of Biologics —  including serums, vaccines, and blood products — 
is transferred from NIH to FDA.
1973
 The U.S. Supreme Court upholds the 1962 drug effectiveness law and endorses 
FDA action to control entire classes of products by regulations rather than to 
rely only on time- consuming litigation.
 Low- acid food pro cessing regulations issued,  after botulism outbreaks from 
canned foods, to ensure that low- acid packaged foods have adequate heat 
treatment and are not hazardous.
 Consumer Product Safety Commission created by Congress; takes over pro-
grams pioneered by FDA  under 1927 Caustic Poison Act, 1960 Federal Haz-
ardous Substances Labeling Act, 1966 Child Protection Act, and PHS accident 
prevention activities for safety of toys, home appliances,  etc.
1976
 Medical Device Amendments passed to ensure safety and effectiveness of 
medical devices, including diagnostic products. The amendments require 
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manufacturers to register with FDA and follow quality control procedures. 
Some products must have pre- market approval by FDA;  others must meet 
per for mance standards before marketing.
 Vitamins and Minerals Amendments (“Proxmire Amendments”) stop FDA 
from establishing standards limiting potency of vitamins and minerals in 
food supplements or regulating them as drugs based solely on potency.
1977
 Saccharin Study and Labeling Act passed by Congress to stop FDA from ban-
ning the chemical sweetener but requiring a label warning that it has been 
found to cause cancer in laboratory animals.
1979
 Introduction of the Bioresearch Monitoring Program as an agency- wide ini-
tiative ensures the quality and integrity of data submitted to FDA and pro-
vides for the protection of  human subjects in clinical  trials by focusing on 
preclinical studies on animals, clinical investigations, and the work of institu-
tional review boards.
 In the hours following the Three Mile Island nuclear emergency of March 28, 
1979, FDA contracted with firms in Missouri, Michigan, and New Jersey 
to prepare and package enough doses of potassium iodide to protect  those 
threatened with thyroid cancer if exposed to radiation. Nearly one quarter of 
a million bottles —  enough for  every  house hold in the area —  were delivered 
to Harrisburg, Pennsylvania within 72 hours.
1980
 Infant Formula Act establishes special FDA controls to ensure necessary 
nutritional content and safety
1981
 FDA and the Department of Health and  Human Ser vices revise regulations 
for  human subject protections, based on the 1979 Belmont Report, which had 
been issued by the National Commission for the Protection of  Human Sub-
jects of Biomedical and Behavioral Research. The revised rules provide for 
wider repre sen ta tion on institutional review boards and they detail ele ments 
of what constitutes informed consent, among other provisions.
1982
 Tamper- resistant Packing Regulations issued by FDA to prevent poisonings 
such as deaths from cyanide placed in Tylenol capsules. The Federal Anti- 
Tampering Act passed in 1983 makes it a crime to tamper with packaged con-
sumer products.
 FDA publishes first Red Book (successor to 1949 “black book”), officially 
known as Toxicological Princi ples for the Safety Assessment of Direct Food 
Additives and Color Additives Used in Food.
Copyright © 2021 Carolina Academic Press, LLC. All rights reserved. 
22 1 · AGENCY STRUCTURE AND PRODUCT CATEGORIES
1983
 Orphan Drug Act passed, enabling FDA to promote research and marketing 
of drugs needed for treating rare diseases.
1984
 Fines Enhancement Laws of 1984 and 1987 amend the U.S. Code to greatly 
increase penalties for all federal offenses. The maximum fine for individuals 
is now $100,000 for each offense and $250,000 if the violation is a felony or 
 causes death. For corporations, the amounts are doubled.
 Drug Price Competition and Patent Term Restoration Act expedites the 
availability of less costly generic drugs by permitting FDA to approve applica-
tions to market generic versions of brand- name drugs without repeating the 
research done to prove them safe and effective. At the same time, the brand- 
name companies can apply for up to five years additional patent protection 
for the new medicines they developed to make up for time lost while their 
products  were  going through FDA’s approval pro cess.
1985
 AIDS test for blood approved by FDA in its first major action to protect 
patients from infected donors.
1986
 Childhood Vaccine Act requires patient information on vaccines, gives FDA 
authority to recall biologics, and authorizes civil penalties.
1987
 Investigational drug regulations revised to expand access to experimental 
drugs for patients with serious diseases with no alternative therapies.
1988
 Food and Drug Administration Act of 1988 officially establishes FDA as an 
agency of the Department of Health and  Human Ser vices with a Commis-
sioner of Food and Drugs appointed by the President with the advice and con-
sent of the Senate, and broadly spells out the responsibilities of the Secretary 
and the Commissioner for research, enforcement, education, and information.
 The Prescription Drug Marketing Act bans the diversion of prescription 
drugs from legitimate commercial channels. Congress finds that the resale 
of such drugs leads to the distribution of mislabeled, adulterated, subpotent, 
and counterfeit drugs to the public. The new law requires drug  wholesalers 
to be licensed by the states; restricts reimportation from other countries; and 
bans sale, trade or purchase of drug samples, and traffic or counterfeiting of 
redeemable drug coupons.
 Generic Animal Drug and Patent Term Restoration Act extends to vet-
erinary products benefits given to  human drugs  under the 1984 Drug Price 
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Competition and Patent Term Restoration Act. Companies can produce 
and sell generic versions of animal drugs approved  after October 1962 with-
out duplicating research done to prove them safe and effective. The act also 
authorizes extension of animal drug patents.
1989
 FDA issues a nationwide recall of all over- the- counter dietary supplements 
containing 100 milligrams or more of L- Tryptophan, due to a clear link 
between the consumption of L- tryptophan tablets and its association with 
a U.S. outbreak of Eosinophilia Myalgia Syndrome (EMS), characterized by 
fatigue, shortness of breath, and other symptoms. By 1990 the Centers for Dis-
ease Control and Prevention confirm over 1,500 cases of EMS, including 38 
deaths, and FDA prohibits the importation of l- tryptophan.
1990
 Responding to increasing illicit traffic, Congress passes the Anabolic Ste roid 
Act of 1990, which identifies anabolic ste roids as a class of drugs and speci-
fies over two dozen items as controlled substances. In addition, a four- part 
definition of this class is established to permit new, black market compounds 
to be assigned to this category, and thus subject to regulation as controlled 
substances.
 Nutrition Labeling and Education Act requires all packaged foods to bear 
nutrition labeling and all health claims for foods to be consistent with terms 
defined by the Secretary of Health and  Human Ser vices. The law preempts 
state requirements about food standards, nutrition labeling, and health 
claims and, for the first time, authorizes some health claims for foods. The 
food ingredient panel, serving sizes, and terms such as “low fat” and “light” 
are standardized.
 Safe Medical Devices Act is passed, requiring nursing homes, hospitals, and 
other facilities that use medical devices to report to FDA incidents that sug-
gest that a medical device prob ably caused or contributed to the death, serious 
illness, or serious injury of a patient. Manufacturers are required to conduct 
post- market surveillance on permanently implanted devices whose failure 
might cause serious harm or death, and to establish methods for tracing and 
locating patients depending on such devices. The act authorizes FDA to order 
device product recalls and other actions.
1991
 Regulations published to Accelerate the Review of Drugs for life- threatening 
diseases.
 The policy for protection of  human subjects in research, promulgated in 1981 
by FDA and the Department of Health and  Human Ser vices, is  adopted by 
more than a dozen federal entities involved in  human subject research and 
becomes known as the Common Rule. This rule issues requirements for 
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researchers who obtain and document informed consent, secures special pro-
tection for  children,  women, and prisoners, elaborates on required procedures 
for institutional review boards, and ensures that research institutions comply 
with the regulations.
1992
 Generic Drug Enforcement Act imposes debarment and other penalties for 
illegal acts involving abbreviated drug applications.
 Prescription Drug User Fee Act requires drug and biologics manufactur-
ers to pay fees for product applications and supplements, and other ser vices. 
The act also requires FDA to use  these funds to hire more reviewers to assess 
applications.
 Mammography Quality Standards Act requires all mammography facilities 
in the United States to be accredited and federally certified as meeting quality 
standards effective Oct. 1, 1994.  After initial certification, facilities must pass 
annual inspections by federal or state inspectors.
 Nutrition facts, basic per- serving nutritional information, are required on 
foods  under the Nutrition Labeling and Education Act of 1990. Based on the 
latest public health recommendations, FDA and the Food Safety and Inspec-
tion Ser vice of the Department of Agriculture re create the food label to list the 
most impor tant nutrients in an easy- to- follow format.
1993
 A consolidation of several adverse reaction reporting systems is launched as 
MedWatch, designed for voluntary reporting of prob lems associated with 
medical products to be filed with FDA by health professionals.
 Revising a policy from 1977 that excluded  women of childbearing potential 
from early drug studies, FDA issues guidelines calling for improved assess-
ments of medi cation responses as a function of gender. Companies are 
encouraged to include patients of both sexes in their investigations of drugs 
and to analyze any gender- specific phenomena.
1994
 Dietary Supplement Health and Education Act establishes specific labeling 
requirements, provides a regulatory framework, and authorizes FDA to pro-
mulgate good manufacturing practice regulations for dietary supplements. 
This act defines “dietary supplements” and “dietary ingredients” and classi-
fies them as food. The act also establishes a commission to recommend how to 
regulate claims.
 FDA announces it could consider regulating nicotine in cigarettes as a drug, 
in response to a Citizen’s Petition by the Co ali tion on Smoking OR Health.
 Uruguay Round Agreements Act extends the patent terms of U.S. drugs from 
17 to 20 years.
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 Animal Medicinal Drug Use Clarification Act allows veterinarians to pre-
scribe extra- label use of veterinary drugs for animals  under specific circum-
stances. In addition, the legislation allows licensed veterinarians to prescribe 
 human drugs for use in animals  under certain conditions.
1995
 FDA declares cigarettes to be “drug delivery devices.” Restrictions are pro-
posed on marketing and sales to reduce smoking by young  people.
 A series of proposed reforms to reduce regulatory burden on phar ma ceu ti-
cal manufacturers is announced, including an expansion of allowable promo-
tional material on approved uses of drugs that firms can distribute to health 
professionals, streamlining certain ele ments in the documentation of investi-
gational drug studies, and a reduction in both environmental impact filings 
and pre- approval requirements in tablet manufacture.
1996
 Federal Tea Tasters Repeal Act repeals the Tea Importation Act of 1897 
to eliminate the Board of Tea Experts and user fees for FDA’s testing of all 
imported tea. Tea itself is still regulated by FDA.
 Saccharin Notice Repeal Act repeals the saccharin notice requirements.
 Animal Drug Availability Act adds flexibility to animal drug approval pro-
cess, providing for flexible labeling and more direct communication between 
drug sponsors and FDA.
 Food Quality Protection Act amends the Food, Drug, and Cosmetic Act, 
eliminating application of the Delaney proviso to pesticides.
1997
 Food and Drug Administration Modernization Act reauthorizes the Pre-
scription Drug User Fee Act of 1992 and mandates the most wide- ranging 
reforms in agency practices since 1938. Provisions include mea sures to accel-
erate review of devices, regulate advertising of unapproved uses of approved 
drugs and devices, and regulate health claims for foods.
1998
 FDA promulgates the Pediatric Rule, a regulation that requires manufacturers 
of selected new and extant drug and biological products to conduct studies to 
assess their safety and efficacy in  children.
 Mammography Quality Standards Reauthorization Act continues 1992 Act 
 until 2002.
 First phase to consolidate FDA laboratories nationwide from 19 facilities to 9 
by 2014 includes dedication of the first of five new regional laboratories.
1999
 ClinicalTrials . gov is founded to provide the public with updated information 
on enrollment in federally and privately supported clinical research, thereby 
expanding patient access to studies of promising therapies.
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 A final rule mandates that all over- the- counter drug labels must contain data 
in a standardized format.  These drug facts are designed to provide the patient 
with easy- to- find information, analogous to the nutrition facts label for foods.
2000
 The U. S. Supreme Court, upholding an  earlier decision in Food and Drug 
Administration v. Brown & Williamson Tobacco Corp. et al., ruled 5–4 that 
FDA does not have authority to regulate tobacco as a drug. Within weeks 
of this ruling, FDA revokes its final rule, issued in 1996, that restricted the 
sale and distribution of cigarettes and smokeless tobacco products to  children 
and adolescents, and that determined that cigarettes and smokeless tobacco 
products are combination products consisting of a drug (nicotine) and device 
components intended to deliver nicotine to the body.
 Federal agencies are required to issue guidelines to maximize the quality, 
objectivity, utility, and integrity of the information they generate, and to pro-
vide a mechanism whereby  those affected can secure correction of informa-
tion that does not meet  these guidelines,  under the Data Quality Act.
 Publication of a rule on dietary supplements defines the type of statement 
that can be labeled regarding the effect of supplements on the structure or 
function of the body.
2002
 The Best Phar ma ceu ti cals for  Children Act improves safety and efficacy of 
patented and off- patent medicines for  children. It continues the exclusivity 
provisions for pediatric drugs as mandated  under the Food and Drug Admin-
istration Modernization Act of 1997, in which market exclusivity of a drug is 
extended by six months, and in exchange the manufacturer carries out stud-
ies of the effects of drugs when taken by  children. The provisions both clar-
ify aspects of the exclusivity period and amend procedures for generic drug 
approval in cases when pediatric guidelines are added to the labeling.
 In the wake of the events of September 11, 2001, the Public Health Security 
and Bioterrorism Preparedness and Response Act of 2002 is designed to 
improve the country’s ability to prevent and respond to public health emer-
gencies, and provisions include a requirement that FDA issue regulations to 
enhance controls over imported and domestically produced commodities it 
regulates.
 Under the Medical Device User Fee and Modernization Act, fees are assessed 
sponsors of medical device applications for evaluation, provisions are estab-
lished for device establishment inspections by accredited third- parties, and 
new requirements emerge for repro cessed single- use devices.
 The Office of Combination Products is formed within the Office of the Com-
missioner, as mandated  under the Medical Device User Fee and Moderniza-
tion Act, to oversee review of products that fall into multiple jurisdictions 
within FDA.
Copyright © 2021 Carolina Academic Press, LLC. All rights reserved. 
 1 · AGENCY STRUCTURE AND PRODUCT CATEGORIES 27
 An effort to enhance and update the regulation of manufacturing pro cesses 
and end- product quality of animal and  human drugs and biological medi-
cines is announced, the current good manufacturing practice (cGMP) ini-
tiative. The goals of the initiative are to focus on the greatest risks to public 
health in manufacturing procedures, to ensure that pro cess and product qual-
ity standards do not impede innovation, and to apply a consistent approach to 
 these issues across FDA.
2003
 The Medicare Prescription Drug Improvement and Modernization Act 
requires, among other ele ments, that a study be made of how current and 
emerging technologies can be utilized to make essential information about 
prescription drugs available to the blind and visually impaired.
 To help consumers choose heart- healthy foods, the Department of Health and 
 Human Ser vices announces that FDA  will require food labels to include trans 
fat content, the first substantive change to the nutrition facts panel on foods 
since the label was changed in 1993.
 An obesity working group is established by the Commissioner of Food and 
Drugs, charged to develop an action plan to deal with the nation’s obesity epi-
demic from the perspective of FDA. In March 2004 the group releases “Calo-
ries Count: Report of the Obesity Working Group,” which addresses issues 
connected to the food label, obesity therapeutics, research needs, the role of 
education, and other topics.
 The National Acad emy of Sciences releases “Scientific Criteria to Ensure Safe 
Food,” a report commissioned by FDA and the Department of Agriculture, 
which buttresses the value of the  Hazard Analy sis and Critical Control Point 
(HACCP) approach to food safety already in place at FDA and invokes the 
need for continued efforts to make food safety a vital part of our overall pub-
lic health mission.
 The Animal Drug User Fee Act permits FDA to collect subsidies for the review 
of certain animal drug applications from sponsors, analogous to laws passed 
for the evaluation of other products FDA regulates, ensuring the safety and 
effectiveness of drugs for animals and the safety of animals used as foodstuffs.
 FDA is given clear authority  under the Pediatric Research Equity Act to 
require that sponsors conduct clinical research into pediatric applications for 
new drugs and biological products.
2004
 Proj ect BioShield Act of 2004 authorizes FDA to expedite its review proce-
dures to enable rapid distribution of treatments as countermea sures to chemi-
cal, biological, and nuclear agents that may be used in a terrorist attack against 
the U. S., among other provisions.
 Passage of the Food Allergy Labeling and Consumer Protection Act requires 
the labeling of any food that contains a protein derived from any one of the 
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following foods that, as a group, account for the vast majority of food aller-
gies: peanuts, soybeans, cow’s milk, eggs, fish, crustacean shellfish, tree nuts, 
and wheat.
 A ban on over- the- counter ste roid precursors, increased penalties for making, 
selling, or possessing illegal ste roids precursors, and funds for preventive edu-
cation to  children are features of the Anabolic Ste roid Control Act of 2004.
 FDA publishes “Innovation or Stagnation? —  Challenge and Opportunity on 
the Critical Path to New Medical Products,” which examines the critical path 
needed to bring therapeutic products to fruition, and how FDA can collabo-
rate in the pro cess, from laboratory to production to end use, to make medical 
breakthroughs available to  those in need as quickly as pos si ble.
 Based on recent results from controlled clinical studies indicating that Cox-2 
selective agents may be connected to an elevated risk of serious cardiovascular 
events, including heart attack and stroke, FDA issues a public health advisory 
urging health professionals to limit the use of  these drugs.
 To provide for the treatment of animal species other than  cattle,  horses, swine, 
chickens, turkeys, dogs, and cats, as well as other species that may be added at 
a  later time, the Minor Use and Minor Species Animal Health Act is passed 
to encourage the development of treatments for species that would other wise 
attract  little interest in the development of veterinary therapies.
 Deeming such products to pre sent an unreasonable risk of harm, FDA bans 
dietary supplements containing ephedrine alkaloids based on an increasing 
number of adverse events linked to  these products and the known pharmacol-
ogy of  these alkaloids.
2005
 Formation of the Drug Safety Board is announced, consisting of FDA staff 
and representatives from the National Institutes of Health and the Veterans 
Administration. The Board  will advise the Director, Center for Drug Evalu-
ation and Research, FDA, on drug safety issues and work with the agency in 
communicating safety information to health professionals and patients.
2009
 President Obama signs the  Family Smoking Prevention and Tobacco Control 
Act into law. The Tobacco Control Act gives FDA authority to regulate the 
manufacture, distribution, and marketing of tobacco products to protect pub-
lic health.
 FDA Center for Tobacco Products established.
 FDA announced a ban on cigarettes with flavors characterizing fruit, candy, 
or clove.
2011
 FDA Food Safety and Modernization Act (FSMA). FSMA provides FDA with 
new enforcement authorities related to food safety standards, gives FDA tools 
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to hold imported foods to the same standards as domestic foods, and directs 
FDA to build an integrated national food safety system in partnership with 
state and local authorities.
2012
 Food and Drug Administration Safety and Innovation Act (FDASIA). 
Expands FDA authorities to collect user fees from industry to fund reviews 
of innovator drugs, medical devices, generic drugs and biosimilar biological 
products; promotes innovation to speed patient access to safe and effective 
products; increases stakeholder involvement in FDA pro cesses, and enhances 
the safety of the drug supply chain.
 Medical Device User Fee and Modernization Act (MDUFMA III). As part 
of FDASIA, reauthorizes user fees from industry to fund reviews of medical 
devices in exchange for FDA to meet certain per for mance goals.
 In 2012, an outbreak of fungal meningitis linked to a contaminated com-
pounded drug product resulted in the loss of 64 lives and caused more than 
751 illnesses. In response, Congress enacted the 2013 Drug Quality and Secu-
rity Act (DQSA) that insures greater regulatory oversight of facilities creating 
compounded drugs.
2013
 Pandemic and All- Hazards Preparedness Reauthorization Act (PAHPRA). 
Establishes and reauthorizes certain programs  under the Public Health Ser-
vice Act and the Food, Drug, and Cosmetic Act with re spect to public health 
security and all- hazards preparedness and response.
 Drug Quality and Security Act. Following an outbreak in 2012 of an epidemic 
of fungal meningitis linked to a compounded ste roid, Congress enacted the 
Drug Quality Safety and Security Act (DQSA). Among other provisions it 
outlines steps for an electronic and interoperable system to identify and trace 
certain prescription drugs throughout the U.S.
[FDA’s milestones list ends in 2013.]
D. Product Categories
The entire structure of food and drug regulation is based on the idea of product 
categories. To know the regulatory requirements that apply to a par tic u lar product, 
you must first know the category into which it falls.
Most categories are initially defined by Congress at the statutory level.  These are 
found in the U.S. Code. Except for the provisions governing biologics,  these are 
found in FFDCA § 201. The provisions governing biologics are found in § 351(i) of 
PHSA. One category,  today known as HCT/Ps, is defined only by regulation, based 
on authority granted in § 361 of the PHSA. Another category, combination products, 
is referenced in FFDCA § 503(g)(1) and defined by regulation in 21 C.F.R. § 3.2.
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Further definition of the product categories is done by FDA at the regulatory 
level.  These are found in the Code of Federal Regulations. They are not consolidated 
in a few areas, as the statutory definitions are. Instead, they tend to be intermixed 
with the other provisions relating to the relevant product category.
1.  Categorization Prob lems
New products do not always fit easily into existing product categories. Some-
times a new product is genuinely outside existing categories. Other times, a product 
potentially fits into two or more categories, but would be subject to heavier regula-
tion in one category than the other.
One of the historically significant product- category disputes reached the U.S. 
Supreme Court in United States v. An Article of Drug . . .  Bacto- Unidisk (1969). 
This case was a dispute over  whether a par tic u lar product, an antibiotic sensitivity 
disk, should be regulated as a drug or a medical device.  Under then- existing law, 
drugs  were subject to marketing authorization for both safety and efficacy. Medical 
devices, by contrast, did not have to undergo any marketing authorization. (This 
would begin to change seven years  later, with the passage of the Medical Device 
Amendments of 1976).
As you read, think about the prob lems associated with regulating industries 
where major innovations often involve previously non ex is tent technology. We  will 
return to Bacto- Unidisk when we discuss both drug and medical device regulation.
Note: In the Bacto- Unidisk case, you  will find several references to FFDCA § 507. 
This provision, specific to antibiotic drugs, was repealed by the Food and Drug Admin-
istration Modernization Act of 1997.  Today, new antibiotic drugs are regulated, like 
other new drugs,  under FFDCA § 505.
United States v. An Article of Drug . . .  Bacto- Unidisk . . . 
394 U.S. 784 (1969)
Mr. Chief Justice WARREN delivered the opinion of the court.
At issue  here is the scope of the statutory definition of drug contained in the 
[FFDCA] and the extent of the Secretary of Health, Education, and Welfare’s regula-
tory authority  under that definition. The specific item involved in this definitional 
controversy is a laboratory aid known as an antibiotic sensitivity disc, used as a screen-
ing test for help in determining the proper antibiotic drug to administer to patients. 
If the article is a “drug” within the general definition of § 201 of the [FFDCA], then 
the Secretary can subject it to pre- market clearance regulations promulgated pursu-
ant to § 507 of the [FFDCA]. Section 507 authorizes the Secretary to require batch 
certification of any antibiotic product which also meets the general drug definition 
of § 201. If, on the other hand, the article is merely a “device”  under the [FFDCA], 
it is subject only to the misbranding and adulteration proscriptions of the [FFDCA] 
Copyright © 2021 Carolina Academic Press, LLC. All rights reserved. 
 1 · AGENCY STRUCTURE AND PRODUCT CATEGORIES 31
and does not have to be pre- tested before marketing; and, of course, if the disc does 
not fall  under  either definition, the [FFDCA] itself is totally inapplicable.
When the discs  were marketed without complying with the certification regu-
lations of the Secretary, the Government condemned them pursuant to § 334 of 
the [FFDCA] on the assumption that the discs  were drugs and thus validly sub-
ject to pre- market regulation. In this action following the condemnation, however, 
the United States District Court for the Eastern District of Michigan held that the 
discs  were not drugs within the meaning of the [FFDCA], suggesting that, if any- 
thing, they  were devices. It therefore ruled that, since pre- market clearance was not 
required or authorized, the seizure was improper. The Court of Appeals for the 
Sixth Cir cuit affirmed on the same reasoning. We reverse.
I.
Some background information about the development of the discs and the control-
ling legislation is necessary for an understanding of the determinations made by 
the Secretary and the courts below. Vari ous antibiotics, known more commonly as 
“won der drugs” . . .  have proved very useful since World War II in treating numer-
ous infectious diseases. Produced biologically, however,  these drugs tend to vary 
greatly in their quality and potency  unless developed, and thereafter tested,  under 
very carefully controlled conditions. Consequently, Congress enacted § 507 of the 
Food, Drug, and Cosmetic Act, directing the Secretary of Health, Education, and 
Welfare to promulgate regulations establishing such standards of identity, potency, 
quality, and purity as necessary to ensure the “safety” and “efficacy” of  those 
antibiotics. . . .
With the proliferation of the vari ous types of antibiotics, doctors found a need 
for a screening test to help choose which antibiotic to use in treating a par tic u lar 
infection. . . .  In this test, a round paper disc, which has been impregnated with a 
specific antibiotic, is placed in contact with sample cultures, or isolates, of a patient’s 
virus, grown in a special culture medium (agar) from a specimen of the patient’s 
fluid (blood, spinal fluid, sputum, urine,  etc.). In  those places impregnated with an 
antibiotic to which the patient’s infection is sensitive, no new isolate  will grow, leav-
ing a clear area (an “inhibition zone”); in  those places impregnated with a drug to 
which the infection is resistant, the isolate  will grow, leaving no clear area. . . .
 After notice and an opportunity for public participation, the Commissioner of 
Food and Drugs,  under authority delegated by the Secretary, promulgated regula-
tions requiring pre- clearance, batch- testing, and certification of antibiotic sensitiv-
ity discs. The Commissioner’s action, the regulations noted, followed “numerous 
complaints by the medical profession, hospitals, and laboratory technicians” and a 
resulting extensive survey of the use of the discs. That study found the discs unre-
liable in their statements of potency with resulting loss of safety and efficacy, and 
thus found it “vital for the protection of the public health” to adopt the regulations.
This case arose in May 1962 as an in rem seizure proceeding against an inter-
state shipment of a number of cases of sensitivity discs, manufactured by Difco 
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Laboratories, Inc.,  under the trade name of “Bacto- Unidisk.” In condemning the 
product pursuant to § 301 et seq. of the Food, Drug, and Cosmetic Act, the United 
States claimed, inter alia, that the product, as a “drug” within the meaning of the 
[FFDCA], had not been certified nor exempted from certification as required by 
§ 507 and the regulations thereunder and was therefore misbranded  under § 502. . . . 
Since the scope of the Secretary’s pre- market regulatory power over antibiotic drugs 
 under § 507 depends ultimately on the [FFDCA]’s general definition of “drug” in 
§ 201(g), the validity of the disc regulations allegedly  violated turned on the cover-
age of the drug definition:
For the purposes of this chapter —  
. . . .
(g)(1) The term ‘drug’ means (A) articles recognized in the official 
United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of 
the United States, or official National Formulary, or any supplement to 
any of them; and (B) articles intended for use in the diagnosis, cure, 
mitigation, treatment, or prevention of disease in man or other animals; 
and (C) articles (other than food) intended to affect the structure or any 
function of the body of man or other animals; and (D) articles intended 
for use as a component of any article specified in clauses (A), (B), or 
(C) of this paragraph; but does not include devices or their components, 
parts, or accessories.
If, on the other hand, the product was a “device,” only the misbranding, adul-
teration, and labeling provisions of §§ 501 and 502 applied, and the Secretary’s disc 
certification regulations  were invalidly promulgated. Although a “device” expressly 
cannot be a “drug”  under the last phrase of the drug definition above, a device is 
given almost a parallel definition in § 201(h):
The term ‘device’ . . .  means instruments, apparatus, and contrivances, 
including their components, parts, and accessories, intended (1) for use in 
the diagnosis, cure, mitigation, treatment, or prevention of disease in man 
or other animals; or (2) to affect the structure or any function of the body 
of man or other animals.
Fi nally, it was established at trial that of the vari ous definitions given above, the 
operative ones in this case  were § 201(g)(1)(B) of the drug provision and § 201(h)(1) 
of the parallel device definition; the essential question under lying the validity of the 
regulations, then, was  whether the Bacto- Unidisks  were “articles intended for use in 
the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other 
animals.”
. . . .  The District Court pointed out that although a “literal reading” of § 201(g)
(1)(B) “clearly has application to the article libeled herein,” enforcing such an appli-
cation would be “ridicu lous and contrary to common sense.” The court therefore 
held that the Bacto- Unidisk did not fall within the purview of the [FFDCA] for the 
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reason that it was not medically a drug, and suggested, without deciding, that the 
discs would be more appropriately classified as “devices”  under the [FFDCA].
On appeal, the Court of Appeals for the Sixth Cir cuit affirmed, accepting the 
District Court’s conclusions that the Bacto- Unidisk was not a “drug” in the medi-
cal sense of the term and that Congress did not intend the statutory definition of 
“drug” to be any broader than the medical one. . . .  We granted the Government’s 
petition for certiorari  because this interpretation of the [FFDCA] raised issues of 
importance in the administration of the [FFDCA].
II.
. . . .  The courts below quite properly confined the inquiry to an examination 
of  whether the disc regulations, even if medically unwise,  were authorized by the 
[FFDCA], and more specifically, by the [FFDCA]’s definition of “drug.” . . .  Our 
sole concern is  whether the statute’s definition of “drug” authorizes the disc regula-
tions contested  here; and while we agree with the lower courts’  limited conception 
of the issue, for reasons outlined below, we reverse their disposition of it.
Respondent’s primary contention  here is that the sensitivity discs are not sub-
ject to any of the provisions of the [FFDCA]  because Congress did not intend it to 
cover articles used so indirectly in the “cure, mitigation, [and] treatment” of dis-
ease. Respondent uses the same two- step analy sis relied on by the courts below: (1) 
Congress did not intend to write the drug definition more broadly than does the 
medical profession, and (2) the medical concept of drug is  limited to articles that 
are administered to man  either internally or externally. Alternatively, respondent 
argues, even if the [FFDCA]’s “in- tended for use” language does cover the discs, 
they must clearly be classified as devices. . . .
We need not stop to parse the language of the [FFDCA]’s definition of drug, for 
the District Court found, and the parties do not disagree  here, that a literal reading 
of the words “intended for use in the . . .  cure, mitigation, [or] treatment” of disease 
“clearly has application” to the Bacto- Unidisk. Although respondent again urges 
that the disc itself does not “treat” a patient in the same way an antibiotic does in 
terms of personal application, the disc plays at least some role in the se lection of 
the appropriate drug. Thus, the essential question for our determination is  whether 
Congress intended the definition of drug to have the broad coverage the courts below 
and the parties agree its words allow. Viewing the structure, the legislative history, 
and the remedial nature of the [FFDCA], we think it plain that Congress intended 
to define “drug” far more broadly than does the medical profession. The reason for 
including a separate, almost parallel, definition of “devices” in the [FFDCA] is, as 
the legislative history shows, relevant to congressional intent. It is therefore helpful 
to consider both the question of the [FFDCA]’s initial application and the question 
of the drug- device dichotomy at the same time.
III.
At the outset, it is clear from § 201 that the word “drug” is a term of art for the 
purposes of the [FFDCA], encompassing far more than the strict medical definition 
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of that word. If Congress had intended to limit the statutory definition to the medi-
cal one, it could have so stated explic itly, or simply have made reference to the offi-
cial United States Pharmacopoeia (or the National Formulary), as it did in the first 
of the three subsections of § 201(g)(1), and let the definition rest  there. The histori-
cal expansion of the statute’s definition, furthermore, clearly points out Congress’ 
intention of  going beyond the medical usage. The 1906 Food and Drug Act, for 
instance, defined “drug” in a rather  limited way to include “all medicines and prep-
arations recognized in the United States Pharmacopoeia or National Formulary for 
internal or external use, and any substance or mixture of substances intended to be 
used for the cure, mitigation, or prevention of disease of  either man or other ani-
mals.” As subsequent congressional action clearly indicates, however, the scope of 
that original definition has since been greatly enlarged.
The enactment of the [FFDCA] illustrates the expansion of the definition of 
drug. One of the changes contemplated in S. 2800, an early version of the [FFDCA], 
defined “drug” to include:
(1) all substances and preparations recognized in the United States Pharma-
copoeia, Homoeopathic Pharmacopoeia of the United States, or National 
Formulary or supplements thereto; and (2) all substances, preparations, 
and devices intended for use in the cure, mitigation, treatment, or preven-
tion of disease in man or other animals; and (3) all substances and prepa-
rations, other than food, and all devices intended to affect the structure or 
any function of the body. [Emphasis on “devices” added by Court.]
Senator Copeland of New York, who sponsored the [FFDCA], remarked about 
the inclusion of the word “devices” in his prepared statement introducing S. 2800 
as follows:
The pre sent law defines drugs as substances or mixtures of substances 
intended to be used for the cure, mitigation, or prevention of disease. This 
narrow definition permits escape from  legal control of all therapeutic or 
curative devices like electric  belts, for example. It also permits the escape of 
preparations which are intended to alter the structure or some function of 
the body, as, for example, preparations intended to reduce excessive weight. 
 There are many worthless and some dangerous devices and preparations 
falling within  these classifications. S. 2800 contains ample authority to con-
trol them.
The definition was revised in S. 5, 74th Cong., 1st Sess. (1935), to include sub-
stances, preparations, and devices in- tended for diagnostic purposes, as well as for 
cure, mitigation, treatment, or prevention of disease. As the inclusion of the word 
“diagnosis” came before the Senate for consideration, a controversy developed on 
the floor, aimed more at the word “devices,” which was not then before the Senate, 
than at the word “diagnosis.” Senator Clark contended that it was not proper to 
classify devices as drugs, and that diagnostic devices  were so broadly defined as to 
make even a bathroom scale a drug:
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If the devices  ought to be outlawed, they  ought to be outlawed, and I have 
no objection to that; but to maintain that a purely mechanical device is a 
drug and to be treated as a drug in law and in logic and in lexicography is a 
palpable absurdity, in my opinion.
In answer to Senator Clark’s remark that a bathroom scale would be classified as 
a drug, Senator Copeland made the following comment:
Mr. President, I desire to state the effect of this amendment.  There are on 
the market certain electrical devices. A man takes hold of the  handles of 
the machine, and the indicator spins around. It stops at ‘appendicitis,’ or it 
stops at ‘meningitis’ . . . .  Such a device is manifestly a fraud upon society. 
That is what the amendment is designed to deal with.
As a result of the criticism on the Senate floor, Senator Copeland proposed an 
amendment to add a definition of “device” to parallel that of drug, an amend-
ment which was included when the bill was returned to the Senate Committee on 
Commerce and  later agreed to by the Senate without debate. The ultimate effect 
of the vari ous amendments, of course, was still to include devices  under the con-
trol of the [FFDCA] for the first time, the goal Senator Copeland had originally 
set out to achieve. . . .  According to the Chief of the Food and Drug Administra-
tion, the reason for providing a separate definition of devices, instead of using 
Senator Copeland’s original drug definition, was simply to avoid “the incongruity 
of classifying certain devices, such as the electric  belt, therapeutic lamps, and so 
forth, as drugs. . . .” (Testimony given during hearings held on S. 5 by a subcom-
mittee of the House Committee on Interstate and Foreign Commerce, 74th Cong., 
1st Sess. (1935).) . . . .  No practical significance to the distinction between the two 
words arose  until the pre- market clearance provisions. . . .  The excepting clause of 
§ 201(g)(1), stating clearly that a drug cannot be a device, was also added in 1938.
The historical expansion of the definition of drug, and the creation of a par-
allel concept of devices, clearly show, we think, that Congress fully intended that 
the [FFDCA]’s coverage be as broad as its literal language indicates —  and equally 
clearly, broader than any strict medical definition might other wise allow. Strong 
indications from legislative history that Congress intended the broad coverage the 
District Court thought “ridicu lous” should satisfy us that the lower courts erred in 
refusing to apply the [FFDCA]’s language as written. But we are all the more con-
vinced that we must give effect to congressional intent in view of the well- accepted 
princi ple that remedial legislation such as the Food, Drug, and Cosmetic Act is to 
be given a liberal construction consistent with the [FFDCA]’s overriding purpose to 
protect the public health, and specifically, § 507’s purpose to ensure that antibiotic 
products marketed serve the public with “efficacy” and “safety.” Cf. United States v. 
 Sullivan, 332 U.S. 689 (1948); United States v. Dotterweich, 320 U.S. 277 (1943).
IV.
Respondent’s alternative contention, that even if its product does fall within 
the purview of the [FFDCA], it is plainly a “device” and therefore by definition 
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necessarily not a “drug,” must also be rejected, we believe, in light of the forego-
ing analy sis. At the outset, it must be conceded that the language of the statute 
is of  little assistance in determining precisely what differentiates a “drug” from 
a “device”: to the extent that both are intended for use in the treatment, mitiga-
tion and cure of disease, the former is an “article” and the latter includes “instru-
ments,” “apparatus,” and “contrivances.” Despite the obvious areas of overlap in 
definition, we are not entirely without guidance in determining the propriety of 
the Secretary’s decision below, given the overall goals of the [FFDCA] and its leg-
islative history.
More specifically, as we have previously held in an analogous situation where the 
statute’s language seemed insufficiently precise, the “natu ral way” to draw the line 
“is in light of the statutory purpose.” Since the patient  will tend to derive less benefit 
and perhaps some harm from a par tic u lar antibiotic if, though the drug itself was 
properly batch- tested, it was not the proper antibiotic to use, it was entirely reason-
able for the Secretary to determine that the discs, like the antibiotics they serve, are 
drugs and similarly subject to pre- clearance certification  under § 507. An opposite 
conclusion might undercut the value of testing the antibiotics themselves, for such 
testing would be a useless exercise if the wrong drug  were ultimately administered, 
even partially as the result of an unreliable disc.
Furthermore, the legislative history, read in light of the statute’s remedial pur-
pose, directs us to read the classification “drug” broadly, and to confine the device 
exception as nearly as is pos si ble to the types of items Congress suggested in the 
debates, such as electric  belts, quack diagnostic scales, and therapeutic lamps, as well 
as bathroom weight scales, shoulder braces, air conditioning units, and crutches. . . . 
Fi nally, we are supported in the decision to uphold the FDA’s determination that 
the sensitivity discs fall  under the coverage of the [FFDCA] and specifically  under 
the drug provision thereof by the knowledge that the classification of  these discs as 
drugs may not be as contrary to common medical usage as the District Court and 
respondent would have us believe.
In upholding the Secretary’s construction of the [FFDCA], we are not unmindful 
of our warning that “in our anxiety to effectuate the congressional purpose of pro-
tecting the public, we must take care not to extend the scope of the statute beyond 
the point where Congress indicated it would stop.” 62 Cases of Jam v. United States, 
340 U.S. 593 (1951). Our holding  here simply involves an obvious corollary to that 
princi ple, that we must take care not to narrow the coverage of a statute short of the 
point where Congress indicated it should extend.
Reversed.
Mr. Justice DOUGLAS, being of the view that an antibiotic sensitivity disc used 
by physicians to aid them in determining what antibiotic drug, if any, to give to a 
patient, is a “device” as defined in § 201(h) of the [FFDCA], not a “drug” as defined 
in § 201(g), would affirm the judgment.
Copyright © 2021 Carolina Academic Press, LLC. All rights reserved. 
 1 · AGENCY STRUCTURE AND PRODUCT CATEGORIES 37
E. Key Points
• FDA is currently based in the Department of Health and  Human Ser vices. 
However, it has a complex orga nizational history. It has previously been  housed 
in other Cabinet- level departments. It has at times acquired new responsibil-
ities from other agencies and it has at times had some of its responsibilities 
transferred to other agencies.
• Product categories are the basis of almost all FDA regulation. The basic cat-
egories addressed in this book are food, food additives, dietary supplements, 
drugs, animal drugs, medical devices, combination products, biologics, HCT/
Ps ( human cells, tissues, and cellular and tissue- based products), cosmetics, 
color additives, and tobacco products.  There are other categories, but  these are 
less critical to a basic understanding of food and drug regulation.
•  There are inevitable disputes about which product category is the correct fit 
for a par tic u lar product.  These disputes can be tremendously impor tant, as 
the regulatory requirements differ dramatically among the dif fer ent product 
categories.
• The dif fer ent regulatory requirements are most significant with re spect to 
marketing authorization (see Chapter 4).
• Products in some categories must undergo rigorous FDA review before 
they can be marketed in the United States.
• Products in other categories can be marketed without any requirement for 
FDA authorization before marketing begins.
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